Divi’s Laboratories is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generics, the Company, through its custom synthesis, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. The Company has two wholly owned subsidiaries which are Divis Laboratories (USA) Inc in USA and Divi’s Laboratories Europe AG in Switzerland; engaged in marketing/distribution of nutraceutical ingredients used in the food, beverage, dietary supplement, feed and pet food industries providing a greater reach to customers within these regions.

Divi's Lab major competitors are Laurus Labs, Neuland Laboratories, Granules India, Acutaas Chemicals, Alivus Life Sciences, Aarti Pharmalabs, Shilpa Medicare.
Market Cap of Divi's Lab is ₹1,64,555 Crs.
While the median market cap of its peers are ₹12,894 Crs.

Divi's Lab seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.